Le Lézard
Classified in: Health, Science and technology
Subjects: Personnel, Award

Mogrify wins Innovation Award and Dr. Jane Osbourn, OBE receives Lifetime Achievement Award at Scrip Awards 2019


Mogrify Ltd (Mogrify), a UK company aiming to transform the development of cell therapies, received MSD's Innovation Award at the 15th Annual Scrip Awards, and the Lifetime Achievement Award was presented to Dr. Jane Osbourn, OBE, Chair at Mogrify. The Innovation Award recognizes the significant potential the Company's direct cellular conversion technology has to disrupt the future development of new medicines. Dr. Osbourn received the Lifetime Achievement Award in recognition of her outstanding contribution to the biotech industry throughout her career.

Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform any human cell type into any other, without going through a pluripotent stem cell- or progenitor cell-state. The Company is using this platform to produce cell types with unrivaled safety, efficacy and scalable manufacturing profiles that can be used to develop novel cell therapies addressing musculoskeletal, auto-immune, cancer immunotherapy, ocular and respiratory diseases.

Dr. Osbourn is a scientific leader in the field of antibody engineering with more than 30 years of experience in biologics discovery and development. During this time she has been Vice President for Research and Development and Site Leader at MedImmune (AstraZeneca), formerly Cambridge Antibody Technology (CAT), Chair of the Board of Directors of the BioIndustry Association, a Director of Babraham Bioscience Technologies, and a Director of Cambridge Enterprise. She has made significant contributions to the discovery and development of phage display technology, eight marketed drugs (including HUMIRA® and BENLYSTA®) and over 40 clinical candidates. Dr. Osbourn holds a doctorate from the John Innes Institute in Norwich, UK and a first-class degree in natural sciences from the University of Cambridge, and was awarded an OBE for services to drug discovery, development and biotechnology.

The Scrip Awards seek to applaud the role that the pharmaceutical, biotech and other allied industries play in improving healthcare. Its trophies span a range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and fundraising. This year's new category, MSD's Innovation Award, acknowledges and celebrates the outstanding scientific or technological breakthroughs that have the potential to be transformative in the discovery or development of new medicines. Scrip's Lifetime Achievement Award is presented to individuals who have had a distinguished career in the biotech or pharmaceutical arena, primarily within industry with a consistent history of exceptional service, throughout their career.

Dr. Darrin M. Disley, OBE, CEO, Mogrify, said: "Our systematic approach to the discovery of novel cell conversions has the potential to transform cell therapy. Mogrify's technology opens up the opportunity to develop and scale up any autologous and allogeneic cell therapies, as well as create a new class of therapies: in vivo reprograming and could therefore have a significant impact on the treatment of degenerative conditions and cancers. We are proud to have our innovative platform and pioneering approach recognized by the judges.

Dr. Osbourn has contributed significantly to the industry throughout her impressive career and is globally renowned for her expertise in biologics discovery and development. She is an inspirational leader and we look forward to celebrating her exceptional achievements."

Dr. Jane Osbourn, OBE, Chair, Mogrify, said "I am honored to have received the Lifetime Achievement Award. Throughout my career I have been fortunate to have worked with many pioneering scientists, who have helped us achieve success in biologics discovery and development. Working together in a diverse team is vital if we are to build great culture and drive innovation. I would like to thank all the extraordinary people who have supported me and I hope to continue to foster many more successful collaborations."

Prof. Jose Polo, CMO (Co-founder) and Prof. Julian Gough, CSO (Co-founder) were presented with the Innovation Award at the prestigious ceremony, which took place in at the London Hilton on Park Lane in Mayfair on 4 December.

For further information about Mogrify's technology and leadership team, please visit:

https://mogrify.co.uk/technology/
https://mogrify.co.uk/about-us/#our-team

 


These press releases may also interest you

at 08:15
Blue Yonder, a leader in digital supply chain transformations, continues its forward momentum to revolutionize the supply chain and has today announced the signing of an agreement to acquire One Network Enterprises (One Network) for approximately...

at 08:15
Maverix Medical, a dedicated lung cancer platform established by Ajax Health, KKR, and Hologic, Inc., today announced the acquisition of Cirrus Bio for an undisclosed amount....

at 08:13
In a significant move to address the heating and cooling needs of European families, Midea's Residential Air Conditioner Division (Midea RAC) unveiled its new CirQHP Family products at the Mostra Convegno Expocomfort (MCE) 2024. The CirQHP Family is...

at 08:00
Bidpath Inc., a leading provider of global online auction software, proudly announces the launch of AuctionPay, a cutting-edge payments platform designed to revolutionize auction payments. With a focus on efficiency, security, and user-centric...

at 08:00
Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that the US Food and Drug...

at 08:00
SC Ventures, Standard Chartered's innovation, fintech investment and ventures arm, is leading a ?12 million (USD $13 million) Series A round for distributed cloud provider Hive, to increase access to sustainable, high-powered computing resources for...



News published on and distributed by: